Shattuck Labs To Present Topline Data From Phase 1 A/B Clinical Trial Of SL-172154 In Relapsed/Refractory Acute Myeloid Leukemia And Higher-Risk Myelodysplastic Syndromes Patients At The ASH 2023 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Shattuck Labs, Inc. (NASDAQ:STTK) has announced the presentation of topline data from its Phase 1 A/B clinical trial of SL-172154, a bi-functional fusion protein for the treatment of patients with cancer and autoimmune disease. The data, which will be presented at the 65th ASH Annual Meeting, shows that SL-172154 demonstrates anti-leukemic activity and an acceptable safety and tolerability profile. The company is encouraged by the growing body of data that further validates the unique mechanism of action of SL-172154 and its therapeutic potential to address the unmet needs for patients with AML and HR-MDS.
November 02, 2023 | 1:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shattuck Labs' announcement of positive topline data from its Phase 1 A/B clinical trial of SL-172154 could potentially boost investor confidence and positively impact the company's stock price in the short term.
The announcement of positive topline data from a clinical trial is typically seen as a positive development for a biotech company. This could lead to increased investor confidence in the company's ability to develop effective treatments, which could in turn lead to an increase in the company's stock price. However, the actual impact will depend on a variety of factors, including the market's overall perception of the company and the biotech sector as a whole.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100